COMMUNIQUÉS West-GlobeNewswire

Nyxoah Announces Closing of Underwritten Public Offering
10/06/2026
REGULATED INFORMATION Nyxoah Announces Closing of Underwritten Public Offering Mont-Saint-Guibert, Belgium – June 10, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/ Nasdaq: NYXH) (“Nyxoah” or the “ [...]
$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch
10/06/2026
$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch Mont-Saint-Guibert, Belgium – June 10, 2026, 10:30 pm CET / 04:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “ [...]
Transactions of Managers and Closely Associated Persons
10/06/2026
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding a transaction of managers and closely associated persons, announcing the allocation of shares to a [...]
RadNet Secures $250 Million Incremental Term Loan to Fund Strategic Growth Opportunities and Reduces the Interest Rates on its Credit Facility by 0.25%
10/06/2026
LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“ RadNet ”), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network [...]
Cytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference
10/06/2026
FREMONT, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that the company will be participating in the upcoming Singular [...]
110 Millions de Dollars de Financements Cumulés pour Accélérer le Lancement Commercial de Genio aux États-Unis
10/06/2026
110 Millions de Dollars de Financements Cumulés pour Accélérer le Lancement Commercial de Genio aux États-Unis Mont-Saint-Guibert, Belgique – 10 juin 2026, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : [...]
Fennec Announces Results of Annual Meeting
10/06/2026
RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April [...]
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
10/06/2026
WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the “Company”) today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock [...]
Oh!mino Releases New Industry Report on Athletes Replacing Supplement Stacks with All-in-One EAA Formulas
10/06/2026
Seal Beach, CA, June 10, 2026 (GLOBE NEWSWIRE) -- Oh!mino today released a new industry report examining the growing trend of athletes replacing supplement stacks with all-in-one essential amino acid (EAA) formulas. The [...]
ThruFlo Endovascular Secures Seed Funding to Advance First Purpose-Built Flow Diverter for Bifurcation Aneurysms
10/06/2026
IRVINE, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- ThruFlo Endovascular, Inc., a neuro-endovascular medical device company, today announced the completion of seed funding led by Atlas MedInnovation (Irvine, CA) to [...]
Cosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries
10/06/2026
CHICAGO, June 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its wholly-owned [...]
Facial Pain Association Celebrates One-Year Anniversary of the Facial Pain Registry
10/06/2026
Registry Marks Milestone with 740 Participants, New Surveys in Development, and Research Proposals Coming This Fall SUWANEE, Ga., June 10, 2026 (GLOBE NEWSWIRE) -- The Facial Pain Association (FPA) is proud to announce [...]
Applied Biologics Presents Interim CAMPX Clinical Trial Data at the Symposium on Advanced Wound Care (SAWC) Spring 2026
10/06/2026
Interim Findings from Prospective Randomized Controlled Trial of XWRAP® Support Continued Enrollment in Chronic Diabetic Foot Ulcer Study SCOTTSDALE, Ariz., June 10, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a [...]
Fedora Pharmaceuticals Expands Scientific Advisory Board with Appointment of Drs. Michael Dudley, Keith Micetich, and Jürgen Bulitta
10/06/2026
Drs. Dudley, Micetich, and Bulitta Join Existing Board of Renowned Infectious Disease Leaders in Common Goal of Advancing Fedora’s Lead Antibiotic Candidate Towards the Clinic EDMONTON, Alberta , June 10, 2026 (GLOBE [...]
Bismarck Women's Health Expert Hosts Free Community Event to Help Women Understand Heavy and Painful Periods
10/06/2026
Featuring Dr. Rhonda Schafer-McLean, a board-certified OB/GYN with more than 15 years of experience caring for women throughout North Dakota BISMARCK, N.D., June 10, 2026 (GLOBE NEWSWIRE) -- Heavy menstrual bleeding and [...]
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
10/06/2026
Ecopipam, an investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track [...]
Procès Verbal de l'Assemblée Générale Ordinaire 2026 d'IBA et Résultats des Votes
10/06/2026
Information réglementée Assemblée Générale Ordinaire du 10 juin 2026 Belgique, le 10 juin 2026 (18h) – Ion Beam Applications SA (« IBA ») annonce que l’ensemble des résolutions proposées à ses actionnaires lors de l’ [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
10/06/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 10 June 2026 at 18.10 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
10/06/2026
Study using Nexalin’s proprietary DIFS ™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up Results further validate [...]

Pages